374 related articles for article (PubMed ID: 10469888)
1. Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids.
Di Marzo V; Bisogno T; De Petrocellis L; Melck D; Martin BR
Curr Med Chem; 1999 Aug; 6(8):721-44. PubMed ID: 10469888
[TBL] [Abstract][Full Text] [Related]
2. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance.
Di Marzo V
Biochim Biophys Acta; 1998 Jun; 1392(2-3):153-75. PubMed ID: 9630590
[TBL] [Abstract][Full Text] [Related]
3. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid receptors and their endogenous agonist, anandamide.
Axelrod J; Felder CC
Neurochem Res; 1998 May; 23(5):575-81. PubMed ID: 9566594
[TBL] [Abstract][Full Text] [Related]
5. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport.
Solinas M; Tanda G; Justinova Z; Wertheim CE; Yasar S; Piomelli D; Vadivel SK; Makriyannis A; Goldberg SR
J Pharmacol Exp Ther; 2007 Apr; 321(1):370-80. PubMed ID: 17210800
[TBL] [Abstract][Full Text] [Related]
6. Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance.
Mallet PE; Beninger RJ
Life Sci; 1998; 62(26):2431-9. PubMed ID: 9651110
[TBL] [Abstract][Full Text] [Related]
7. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance.
Sugiura T; Kobayashi Y; Oka S; Waku K
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):173-92. PubMed ID: 12052034
[TBL] [Abstract][Full Text] [Related]
8. Natural and synthetic endocannabinoids and their structure-activity relationships.
Palmer SL; Khanolkar AD; Makriyannis A
Curr Pharm Des; 2000 Sep; 6(13):1381-97. PubMed ID: 10903399
[TBL] [Abstract][Full Text] [Related]
9. A hydrolase enzyme inactivating endogenous ligands for cannabinoid receptors.
Ueda N; Goparaju SK; Katayama K; Kurahashi Y; Suzuki H; Yamamoto S
J Med Invest; 1998 Aug; 45(1-4):27-36. PubMed ID: 9864962
[TBL] [Abstract][Full Text] [Related]
10. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
Shivachar AC; Martin BR; Ellis EF
Biochem Pharmacol; 1996 Mar; 51(5):669-76. PubMed ID: 8615904
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments.
Di Marzo V; De Petrocellis L; Bisogno T; Melck D
Lipids; 1999; 34 Suppl():S319-25. PubMed ID: 10419192
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of cannabimimetic effects of structural analogs of anandamide in rats.
Wiley JL; Ryan WJ; Razdan RK; Martin BR
Eur J Pharmacol; 1998 Aug; 355(2-3):113-8. PubMed ID: 9760024
[TBL] [Abstract][Full Text] [Related]
13. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
14. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.
Gubellini P; Picconi B; Bari M; Battista N; Calabresi P; Centonze D; Bernardi G; Finazzi-Agrò A; Maccarrone M
J Neurosci; 2002 Aug; 22(16):6900-7. PubMed ID: 12177188
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys.
Wiley JL; Golden KM; Ryan WJ; Balster RL; Razdan RK; Martin BR
Pharmacol Biochem Behav; 1997 Dec; 58(4):1139-43. PubMed ID: 9408225
[TBL] [Abstract][Full Text] [Related]
16. Cannabinergic ligands.
Palmer SL; Thakur GA; Makriyannis A
Chem Phys Lipids; 2002 Dec; 121(1-2):3-19. PubMed ID: 12505686
[TBL] [Abstract][Full Text] [Related]
17. Endocannabinoids.
Mechoulam R; Fride E; Di Marzo V
Eur J Pharmacol; 1998 Oct; 359(1):1-18. PubMed ID: 9831287
[TBL] [Abstract][Full Text] [Related]
18. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
19. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase.
Reggio PH; Traore H
Chem Phys Lipids; 2000 Nov; 108(1-2):15-35. PubMed ID: 11106780
[TBL] [Abstract][Full Text] [Related]
20. Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner.
Barana A; Amorós I; Caballero R; Gómez R; Osuna L; Lillo MP; Blázquez C; Guzmán M; Delpón E; Tamargo J
Cardiovasc Res; 2010 Jan; 85(1):56-67. PubMed ID: 19689982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
